NCT02823964View on ClinicalTrials.gov

EASY: Extended Access to Sollpura Over Years

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Exocrine Pancreatic InsufficiencyCystic Fibrosis
Interventions
DRUG

Liprotamase

Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement

Trial Locations (15)

2045

Investigator Site 302, Törökbálint

4031

Investigator Site 303, Debrecen

7257

Investigator Site 304, Mosdós

8400

Investigator Site 301, Ajka

28046

Investigator Site 401, Madrid

39216

Investigator Site 134, Jackson

80045

Investigator Site 114, Aurora

9124001

Investigator Site 601, Jerusalem

05401

Investigator Site 121, Burlington

625 00

Investigator Site 501, Brno

58-540

Investigator Site 203, Karpacz

90-329

Investigator Site 206, Lodz

20-362

Investigator Site 205, Lublin

34-700

Investigator Site 202, Rabka-Zdrój

35-612

Investigator Site 209, Rzeszów

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT02823964 - EASY: Extended Access to Sollpura Over Years | Biotech Hunter | Biotech Hunter